Nobiletin (NSC 76751)

Catalog No.S2333 Synonyms: Hexamethoxyflavone

For research use only.

Nobiletin (NSC 76751, Hexamethoxyflavone), a citrus flavonoid isolated from citrus peels like in tangerine, which has anti-inflammatory and anti-tumor activities.

Nobiletin (NSC 76751) Chemical Structure

CAS No. 478-01-3

Selleck's Nobiletin (NSC 76751) has been cited by 12 Publications

1 Customer Review

Purity & Quality Control

Choose Selective MMP Inhibitors

Other MMP Products

Biological Activity

Description Nobiletin (NSC 76751, Hexamethoxyflavone), a citrus flavonoid isolated from citrus peels like in tangerine, which has anti-inflammatory and anti-tumor activities.
Targets
MMP [1]
In vitro

Nobiletin, a citrus flavonoid isolated from citrus peels like in tangerine, which has anti-inflammatory and anti-tumor activities. Nobiletin, a polymethoxyflavonoid, is identified as an inhibitor of both NO and O 2- generation. Nobiletin significantly inhibites two skin inflammation induced by double TPA application. It also suppresses the expression of cyclooxygenase-2 and inducible NO synthase proteins and prostaglandin E2 release. [1] Nobiletin inhibites the tumor-invasive activity of human fibrosarcoma HT-1080 cells in the Matrigel model, not only by suppressing the expression of MMPs but also augmenting TIMP-1 production through interfering the phosphatidylinositol 3-kinase pathway (PI3-K). [2] Nobiletin may also prevent atherosclerosis at the level of the vascular wall by inhibiting macrophage foam-cell formation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MX NIjHemRHfW6ldHnvckBie3OjeR?= NFjKOXhKdmirYnn0bY9vKG:oIFLDVnAh\XiycnXzd4VlKGmwIF3DSk04KE2[IHPlcIx{KHW|aX7nJGhw\WOqc4SgN|M{PDJic4ThbY5qdmduIFnDOVA:PC52zszN MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN3NEiwNEc,OjF|NUS4NFA9N2F-
MDCK NH3GUIxHfW6ldHnvckBie3OjeR?= NW\RPYdrUW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CCrbjDNSGNMKGOnbHzzJJV{cW6pIFjv[YNpe3RiM{OzOFIhe3SjaX7pcoctKEmFNUC9OE46|ryP NXPNfIN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOVQ5ODBpPkKxN|U1QDByPD;hQi=>
NIH-3T3-G185 M1:ySGZ2dmO2aX;uJIF{e2G7 NEiyOo5VWF:WUlHOV3BQWlSHUkqgbY5pcWKrdHnvckBw\iCGYYXuc5J2[mmlaX6g[YZndHW6IHnuJG5KUC1|VEOtS|E5PSClZXzsd{whUUN3ME2xNU42|ryP NXHWemt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3OFM4PDJpPkGxO|Q{PzR{PD;hQi=>
SRA 01/04 NVyyfXZSTnWwY4Tpc44h[XO|YYm= MmHPNlQhcHK| NWXwWodnUW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGtbY5lfWOnZDDwdo9OVVB7IIDyc4R2[3Srb36gbY4hcHWvYX6gV3JCKDBzL{C0JINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCVRGOtVGFITSCjbnHsfZNqeyxiSVO1NF0yP87:TR?= NHPrd4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUeyN|czPid-MkG3NlM4OjZ:L3G+
SRA 01/04 MVrGeY5kfGmxbjDhd5NigQ>? MkDVNlQhcHK| NX\5WlJyUW6qaXLpeIlwdiCxZjDUUmZidHCqYT3zeIlufWyjdHXkJJBzdyCPTWC5JJBzd2S3Y4Tpc44hcW5iaIXtZY4hW1KDIECxM|A1KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDTSHMuWEGJRTDiZZNm\CCpZXzheIlvKHq7bX;ndoFxcHliYYPzZZktKEmFNUC9NVfPxE1? MmLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyNEe3PVgoRjJ{MES3O|k5RC:jPh?=
SRA 01/04 NFHZSmNHfW6ldHnvckBie3OjeR?= NI\5[mMzPCCqcoO= NUDieGtnUW6qaXLpeIlwdiCxZjDQUWEucW6mdXPl[EBxem:PTWC5JJBzd2S3Y4Tpc44hcW5iaIXtZY4hW1KDIECxM|A1KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDTSHMuWEGJRTDhcoFtgXOrczygTWM2OD1{MD65{txO NF3hS2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUeyN|czPid-MkG3NlM4OjZ:L3G+
SRA 01/04 M2DSSGZ2dmO2aX;uJIF{e2G7 MYGyOEBpenN? NGHQcYJKdmirYnn0bY9vKG:oIGDNRU1{fGmvdXzheIVlKHC{bzDNUXA6KHC{b3T1Z5Rqd25iaX6gbJVu[W5iU2LBJFAyNzB2IHPlcIx{KGGodHXyJFI1KGi{czDifUBUTFNvUFHHSUBj[XOnZDDn[YxifGmwIIr5cY9oemGyaImgZZN{[XluIFnDOVA:OjBwOd88US=> MnPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyNEe3PVgoRjJ{MES3O|k5RC:jPh?=
HT-29 M4TQ[WFvfGmlYX7j[ZIh[XO|YYm= NEfRe3g4OiCqcoO= NE\XWZFCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOO69VQ>? NUPNOplkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwOVQ3PzdpPkG5NFU1Pjd5PD;hQi=>
SHSY5Y MVLGeY5kfGmxbjDhd5NigQ>? NICzPJUyOiCqcoO= NIL2O3NT\WS3Y4Tpc44hd2ZiaInkdo9o\W5icHXyc5hq\GVvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aDDpckBpfW2jbjDTTHN[PVliY3XscJMh[XO|ZYPz[YQh[XNiRF7BJIxi\GSncjDmc5Ju[XSrb36gZYZ1\XJiMUKgbJJ{ NVTTO41[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyPFI4PTdpPkG4NlgzPzV5PD;hQi=>
SHSY5Y MWjGeY5kfGmxbjDhd5NigQ>? M3PsSlMxKHWP M1Xod|MhcHK| M2fCfmVt\X[jdHnvckBw\iCyaH;zdIhwenmuYYTl[EBGWktibHX2[YwhcW5iaInkdo9o\W5icHXyc5hq\GVvdILlZZRm\CCqdX3hckBUUFO\NWmgZ4VtdHNiYYSgN|AhfU1iYX\0[ZIhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NIjiUYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK4Nlc2Pyd-MUiyPFI4PTd:L3G+
SHSY5Y NGrRUpZHfW6ldHnvckBie3OjeR?= MkC1N|AhfU1? M{fuXlMhcHK| M2rFWWVt\X[jdHnvckBw\iCyaH;zdIhwenmuYYTl[EBxOzhibHX2[YwhcW5iaInkdo9o\W5icHXyc5hq\GVvdILlZZRm\CCqdX3hckBUUFO\NWmgZ4VtdHNiYYSgN|AhfU1iYX\0[ZIhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ6Mke1O{c,OTh{OEK3OVc9N2F-
SHSY5Y MYDGeY5kfGmxbjDhd5NigQ>? NGTtb5Y{OCC3TR?= MX6zJIhzew>? M4HiUGVt\X[jdHnvckBw\iCyaH;zdIhwenmuYYTl[EBLVmtibHX2[YwhcW5iaInkdo9o\W5icHXyc5hq\GVvdILlZZRm\CCqdX3hckBUUFO\NWmgZ4VtdHNiYYSgN|AhfU1iYX\0[ZIhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M3OwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkiyO|U4Lz5zOEK4Nlc2PzxxYU6=
ST-13 MnHxSpVv[3Srb36gZZN{[Xl? M4jWWFExKHWP MkLnNVEh\GG7cx?= NUT5Xld[UW6mdXP0bY9vKG:oIIDy[YFlcXCxY4n0[UBlcW[oZYLlcpRq[XSrb36gbY4hdW:3c3WgV3QuOTNiY3XscJMh[XO|ZYPz[YQh[XNibHnwbYQh[WOldX31cIF1cW:wIHH0JFExKHWPIIfpeIhqdiBzMTDkZZl{KGK7IH;pcEBz\WRvc4ThbY5qdmdicnXsZZRqfmVidH:gZ49vfHKxbB?= NFXGOlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK2PFU5Pyd-MUmyOlg2QDd:L3G+
ST-13 M2[0SmZ2dmO2aX;uJIF{e2G7 NXPOUlJbOC5zIITvJFMxKHWP MUKxNUBl[Xm| MXHJcoR2[3Srb36gc4Yh[WSrcH;jfZRmKGSrZn\ldoVvfGmjdHnvckBqdiCvb4Xz[UBUXC1zMzDj[YxteyCjc4Pld5Nm\CCjczDzeIlufWyjdHnvckBw\iCjZHnwd4lvKG2UTlGg[ZhxemW|c3nvckBifCByLkGgeI8hOzBidV2ge4l1cGmwIEGxJIRigXNiYomgd4VucS2zdXHueIl1[XSrdnWgVnQuWEOU M{Oze|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mk[4OVg4Lz5zOUK2PFU5PzxxYU6=
ST-13 Ml3TSpVv[3Srb36gZZN{[Xl? NVjOcYFVOC5zIITvJFMxKHWP NXvGUpRpOTFiZHH5dy=> Mm[4TY5lfWO2aX;uJI9nKGGmaYDvZ5l1\SCmaX\m[ZJmdnSrYYTpc44hcW5ibX;1d4UhW1RvMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgd5RqdXWuYYTpc44hd2ZiYXTpdI9kgXSnIGCyJI1TVkFiZYjwdoV{e2mxbjDheEAxNjFidH:gN|AhfU1id3n0bIlvKDFzIHThfZMh[nlic3XtbU1yfWGwdHn0ZZRqfmViUmStVGNT M2\xblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mk[4OVg4Lz5zOUK2PFU5PzxxYU6=
ST-13 NUDxW5E3TnWwY4Tpc44h[XO|YYm= NY\XdnZyOTFiZHH5dy=> M3HFcWlv\HWldHnvckBw\iCjZHnwc4N6fGViZHnm[oVz\W62aXH0bY9vKGmwIH3veZNmKFOWLUGzJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFCSQWLnZY1u[TJibWLORUBt\X[nbDDh[pRmeiBzMTDkZZl{KGK7IIPlcYkueXWjboTpeIF1cX[nIGLUMXBEWiC{ZXzheIl3\SC2bzDjc451em:u NX\SXWZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOlg2QDdpPkG5NlY5PTh5PD;hQi=>
SRA 01/04 MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkPROlQhfU1? NUHaTIlmPCCmYYnz NX:2VGJwT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1KDIECxM|A1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDQR25CKGW6cILld5Nqd25iYYSgOlQhfU1iYX\0[ZIhPCCmYYnzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NVHSeY5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxPVk5QDJpPkKzNVk6QDh{PD;hQi=>
In vivo LD50: 780mg/kg (i.g.). [4]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 402.39
Formula

C21H22O8

CAS No. 478-01-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Nobiletin (NSC 76751) | Nobiletin (NSC 76751) supplier | purchase Nobiletin (NSC 76751) | Nobiletin (NSC 76751) cost | Nobiletin (NSC 76751) manufacturer | order Nobiletin (NSC 76751) | Nobiletin (NSC 76751) distributor